CORRELATION OF SERUM LEVELS OF TRANSFORMING GROWTH FACTOR β WITH CLINICAL, INSTRUMENTAL AND LABORATORY MARKERS OF CHRONIC HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION
https://doi.org/10.29001/2073-8552-2016-31-2-57-60
Abstract
Despite the presence of multiple biomarkers, no “gold standard” has been identified yet to serve as a reliable tool for pharmacotherapy effectiveness monitoring, early diagnosis, clinical outcome prognosis, and risk stratification of patients with chronic heart failure with preserved ejection fraction (HFpEF) of the left ventricle. Goal: The goal of the study was to investigate correlations of the levels of serum transforming growth factor β (TGF-β1) with clinical, instrumental, and laboratory markers of HFpEF. Materials and Methods. This clinical and pathophysiological study comprised 27 patients with HFpEF. Results. Correlation relationships were found for left ventricular myocardial mass, intraventricular septum thickness, serum level of tissue inhibitor of metalloproteinases(1 (TIMP-1), and serum level of matrix metalloproteinase 3 (MMP-3). Multiple regression analysis demonstrated the presence of a relationship between TGF(β1 and TIMP-1. The study revealed relationships of serum TGF-β level with clinical and instrumental indicators of myocardial hypertrophy and serum levels of TIMP-1 and MMP-3 in patients with HFpEF.
About the Authors
A. M. Boiko
Siberian State Medical University, Tomsk;
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
V. S. Shurupov
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
T. E. Suslova
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk
Russian Federation
Russian Federation
V. V. Ryabov
Siberian State Medical University, Tomsk;
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”, Tomsk;
National Research Tomsk State University
Russian Federation
Russian Federation
References
1. Всемирная организация здравоохранения [Электронный ресурс] // Информационный бюллетень № 317 Январь 2015 г. – URL: http://www.who.int/mediacentre/factsheets/fs317/ru/ (дата обращения: 29.12.2015).
2. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и ле( чению ХСН (четвертый пересмотр) // Сердечн. недостат. – 2013 – Т. 14(7). – С. 379–472.
3. Марков В.А., Рябов В.В., Вышлов Е.В. и др. Особенности ре( моделирования сердца после инфаркта миокарда при фармакоинвазивных методах реперфузии и усиленной наруж( ной контрпульсации. – Томск : STT, 2014. – 244 с.
4. Lang R.M., Badano L.P., Mor(Avi V. et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // J. Am. Soc. Echocardiogr. – 2015. – Vol. 28(1). – Р. 1–39.
5. Ryabov V., Kravchenko E., Suslova T. Circulating Matrix Metalloproteinases, Tissue Inhibitors, Natriuretic peptides, and Rigidity of the Great Arteries in Patients with HFpEF in 12 Month after Myocardial Infarction // Advanced Materials Research. – 2015. – Vol. 1085. – P. 406–413.
6. Ryabov V., Shurupov V., Suslova T., Markov V. Arterial stiffness in patients with heart failure and preserved ejection fraction 12 months after myocardial infarction // Polski Przeglad Kardiologiczny. – 2012. – Vol. 14, No. 3. – P. 165–172.
7. Базаева Е.В., Мясников Р.П., Метельская В.А. и др. Диагностическая значимость биологических маркеров при хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка // Сердечн. недостат. – 2015. – Т. 16(1). – С. 43–51.
8. Izumiya Y., Hanatani S., Kimura Y. et al. Growth Differentiation Factor(15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction // Can. J. Cardiol. – 2014 Mar. – Vol. 30(3). – P. 338–344.
9. Hsich E.M., Grau(Sepulveda M.V., Hernadez A.F. et al. Relationship between sex, ejection fraction, and B(type natriuretic peptide levels in patients hospitalized with hert failure and associations with in hospital outcomes: findings from the get with the Guideline(Heart Failure Registry // Am. Heart J. – 2013, Dec. – Vol. 166(6). – P. 1063–1071.
10. De Denus S., Lavoie J., Ducharme A. et al. Differences in biomarkers in patients witch heart failure with a reduced vs a preserved left ventricular ejection fraction // Can. J. Cardiol. – 2012 Jan(Feb. – Vol. 28(1). – P. 62–68.
11. Mason J.M., Hacock H.C., Close H. et al. Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the Heart Failure in Care Homes (HFinCH) diagnostic accuracy study // PloS One. – 2013. – Vol. 8(1). – P. e535560.
12. Andrea R., Falces C., Sanchis L. et al. Diagnosis of heart failure with preserved or reduced ejection fraction in a one(stop clinic // Aten Primaria. – 2013 Apr. – Vol. 45(4). – P. 184–192.
13. Stahrenberg R., Edelmann F., Mende M. et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction // Eur. J. Heart Fail. – 2010, Dec. – Vol. 12(12). – P. 1309–1316.
Review
For citations:
Boiko A.M., Shurupov V.S., Suslova T.E., Ryabov V.V. CORRELATION OF SERUM LEVELS OF TRANSFORMING GROWTH FACTOR β WITH CLINICAL, INSTRUMENTAL AND LABORATORY MARKERS OF CHRONIC HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION. Siberian Journal of Clinical and Experimental Medicine. 2016;31(2):57-60. (In Russ.) https://doi.org/10.29001/2073-8552-2016-31-2-57-60
Views:
342
.png)
Email this article 